嘧肽霉素高产菌株的选育

以不吸水链霉菌辽宁变种为出发菌株,经紫外线、亚硝酸诱变和紫外线与嘧肽霉素复合诱变,选育出了嘧肽霉素的高产菌株,抑菌圈直径由原来的20.5mm提高到36.4mm。传代培养5代表明,该高产菌株遗传特性稳定。     

欧拉羊与山谷型藏羊杂交后代各年龄段生长速度分析

对欧拉羊与山谷型藏羊杂交试验组和山谷型藏羊本交对照组所产的后代进行了初生、3月龄、6月龄、12月龄、18月龄的体重跟踪测定和差异显著性检验。结果表明,欧山杂交F1代公、母羊初生～3月龄,3～6月龄,6～12月龄、12～18月龄日增重分别比同期对照组后代日增重均快,差异极显著(P﹤0.01),并且随着月龄的增加,日增重降低。说明欧山杂交后代的生长速度在初生至12月龄增长速度快,而12～18月龄的增长速度减慢,适宜羔羊肉生产。     

益生菌Lactobacillus casei|Zhang 高密度发酵中试工艺及动力学研究

在益生菌L.caseiZhang高密度培养小试（3L）基础上,进行30L到150L逐级放大中试生产工艺的研究以确定规模化生产工艺。在优化的发酵工艺下,150L规模发酵菌体密度可达2.9×10^10cfu/mL,与小试水平无差异。采用origin7.5软件在logistic equation基础上建立L.caseiZhang的生长和葡萄糖代谢动力学模型,模型与试验值拟合良好,平均误差小于10%,能够较好地反应发酵过程。初步探讨发酵后菌体的离心和冷冻干燥过程对菌体的影响,虽然发酵液经离心收集菌体后冷冻干燥可得到平均活菌数2.65×10^11cfu/g的菌粉,能够满足益生菌制剂和发酵剂对高活菌数的要求,但冻干前后活菌得率仅49.97%。有必要针对L.casei Zhang的冻干保护剂和冻干工艺进一步优化,以提高菌体存活率得到更高菌体浓度的益生菌粉。     

Vaccination and challenge studies with psittacine beak and feather disease virus

SUMMARY: Psittacine beak and feather disease virus (PBFDV) was administered to adult galahs ( Eolophusroselcapillus ) by mouth or by intramuscular injection. Concentration of PBFDV antibodies in serum and excretion of PBFDV were monitored by haemagglutlnation inhibition (HI) and haemagglutination (HA) respectively. After oral administration, 17 of 18 galahs remained clinically normal and a small rise in antibody titre was detected in 3 of 18 birds. After intramuscular administration, antibody was detected in all birds. PBFDV was not detected in the feather dander of birds in either group. One bird developed diarrhoea and high faecal HA titres within 4 days of oral administration and then died. Adult and nestling cockatoos were vaccinated with an experimental inactivated double-oil emulsion vaccine. PBFDV antibody responses are comparable to those induced by a primary-oil emulsion vaccination regimen using Freund's adjuvants. Both vaccines protected nestlings. Three sibling wild-caught sulphur-crested cockatoos were vaccinated but died of PBFD before experimental challenge despite antibody responses in all birds. Unvaccinated control chicks developed acute PBFD within 4 weeks of challenge, probably from PBFDV-induced hepatitis since high concentrations of PBFDV were detected in their livers.     

陶藏杂一代羔羊与藏羔羊育肥效果比较研究

试验选择体重相近、健康良好的无角陶赛特羊与藏羊杂一代羔羊28只,藏羊羔羊15只进行育肥,测定其育肥效果。结果表明,试验组绝对增重、平均日增重和相对增重分别比对照组提高4．35kg、72．5g／d和23．87％,差异显著（P〈0．05）;试验组胴体重、屠宰率分别较对照组提高4．55kg和4．74％,差异显著（P〈0．05）,试验组GR值和眼肌面积分别较对照组提高2．12cm。和0．7mm,但差异不显著（P〉0．05）;经济效益分析表明,育肥后杂一代羊较藏羊多收入174．0元／只。     

Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus

Objective To develop a serotype 1 Marek's disease (MD) vaccine from a very virulent MDV (vvMDV) pathotype and demonstrate safety and efficacy against early challenge with very virulent field strains in the presence of maternal antibody.
Study design Strain BH 16 was isolated and attenuated by serial cell culture passage. One of two cloned passages was selected for vaccine development following early laboratory-scale protection trials in commercial birds. Comparative protection trials were carried out on the BH 16 vaccine and on a CVI 988 Rispens vaccine using commercial and SPF chickens. Challenge viruses used were either a low passage strain BH 16 virus, the Woodlands No. 1 strain or MPF 57 strain of MDV. The BH 16 vaccine was back-passaged in SPF chickens six times and virus recovered from the final passage and the original vaccine virus were tested for safety. The immunosuppressive potential of the BH 16 and Rispens vaccines was also assessed in parallel.
Results The BH 16 and Rispens vaccines induced comparable levels of protection when used as monovalent or multi-valent vaccines, although protection achieved with the mono-valent vaccines was lower. No gross tumour formation was evident in any birds receiving the BH 16 vaccine or bird-passaged virus, although microscopic lesions were present in 2/12 birds that received the bird-passaged virus. In tests for immunosuppression, there was no histological evidence of damage to either the bursa of Fabricius or the thymus.
Conclusion The BH 16 vaccine was shown to be safe and at least as protective as the Rispens vaccine against three highly virulent MD challenge viruses.     

欧拉羊与山谷型藏羊杂交效果观察初报

引进草地型藏羊欧拉羊杂交改良山谷型藏羊,结果表明:引进的欧拉羊生理指标正常,对在林间草甸类和高山灌丛草场与山谷型藏羊同群放牧较适应;试验组受胎率、繁殖率、繁殖成活率比对照组分别高2.65%、2.69%、3.81%;欧×山杂交F1代初生公、母羊体高、体长、胸围及管围比同期对照组公、母羊分别提高了3.20 cm和4.50 cm、1.97 cm和2.25 cm、4.10 cm和2.20 cm、0.53cm和0.40 cm;体重提高0.62 kg和0.53 kg,比对照组分别提高了19.68个百分点和17.97个百分点。经过t检验,杂交F1代初生公、母羊体重、体高、体长、胸围极显著的高于对照组初生公、母羊(P0.01);管围差异显著(P0.05)。     

干草原区植被保护支持技术研究绿色添加剂—大蒜(Allium sativum)对肉牛增重影响的研究

大蒜是一种植物鳞茎 ,作为肉牛饲料添加剂尚未见报道。本文研究的目的是 :研究大蒜对肉牛增重的影响。试验选用西门塔尔杂交后代公牛 3 8头其中 3 5头牛随机分为七组 ,大蒜组 A( 50 g/ d.头 )、D( 1 0 0 g/ d.头 )、F( 1 50 g/ d.头 ) ;大蒜素组 C( 0 .2 g/ d.头 )、E( 0 .4g/ d.头 )、G( 0 .6g/ d.头 ) ;对照组。试验采用完全拉丁方设计。试验结果表明 :1 .大蒜在添加 74.6g/ d.头左右 ,对肉牛增重有明显的促进作用 ,Y=-0 .0 0 2 2 x2 +0 .3 2 8x+2 8.3 2 ,R2 =0 .972 8( Y为增重 ,X大蒜用量 )。 2 .当大蒜素添加量为 0 .3 5g/ d.头时肉牛体增重最高 ,y=-92 .5x2 +65.4x+2 7.3 3 R2 =0 .91 96( Y为增重 ,X大蒜素用量 )。 3 .大蒜促进肉牛增重的主要成分是大蒜素     

Development and trial of a bovine herpesvirus 1 - thymidine kinase deletion virus as a vaccine

SUMMARY An Australian bovine herpesvirus 1 (BHV1) isolate with a defined (427 base pair) deletion in the protein coding region of the thymidine kinase gene was obtained by standard marker rescue procedures. After selection in the presence of the nucleotide analogue 5iodo-deoxy-uridine the virus was analysed by hybridisation with three differential oligonucleotide probes, restriction endonuclease profile studies and DNA sequence analysis. The virus elicited an immune response in recipient animals after either intramuscular or intravenous administration and produced no significant deleterious side-effects when administered at a dose sufficient to stimulate the host immune response. The safety and immunogenicity of the recombinant BHV1 virus 39B1 were similar to those reported for other registered BHV1 vaccines and the virus would appear to be suitable for the production of a vaccine seed lot and more exhaustive field trials as a prelude to commercial vaccine production and registration.